Stock listing

Munich:CUS0 Curis, Inc. Aktie

German listing (Munich) of Curis, Inc. · home listing NASDAQ:CRIS

Follow Curis, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CRIS

$0.427 USD -0.042 (-9.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRIS

Past year -98.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.420 – $0.494 USDNov 20, 2026
Volume
524,812 sharesNov 20, 2026
Market cap
$2.85M USDAt the close on Nov 20, 2026 · price × 6.68M shares outstanding
52-week range
$0.330 – $28.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.95M USDMedian day 182,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Curis, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRIS · Home$0.427 USD-0.042 (-9.0%)524,812$0.473$0.494$0.420$0.469Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRIS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.427-0.042-9.0%$0.473$0.494$0.420524,812
$0.469-0.145-23.6%$0.592$0.605$0.4601,258,887
$0.614+0.073+13.4%$0.527$0.614$0.48310,640,979
$0.542+0.106+24.3%$0.471$0.550$0.44912,675,005
$0.436-0.014-3.2%$0.420$0.470$0.416469,701
$0.450-0.120-21.1%$0.500$0.500$0.430720,500
$0.570-0.020-3.4%$0.600$0.610$0.540528,100
$0.590-0.060-9.2%$0.640$0.660$0.560513,100
$0.650-0.050-7.1%$0.640$0.660$0.5601,307,200
$0.700-0.210-23.1%$0.890$0.900$0.6801,742,200
$0.910+0.060+7.1%$0.800$0.950$0.7602,605,500
$0.850-0.260-23.4%$0.990$1.090$0.83011,916,900
$1.110+0.400+56.3%$1.350$1.600$1.060163,533,100
$0.710+0.050+7.6%$0.720$1.500$0.62051,139,200
$0.660+0.060+10.0%$0.580$0.760$0.5701,093,800
$0.600+0.050+9.1%$0.550$0.650$0.470913,200
$0.550+0.100+22.2%$0.460$0.670$0.4506,414,200
$0.450+0.050+12.5%$0.410$0.450$0.400252,200
$0.400+0.020+5.3%$0.380$0.410$0.370237,700
$0.380-0.010-2.6%$0.410$0.410$0.360315,500
$0.390-0.010-2.5%$0.410$0.420$0.38066,900
$0.400+0.010+2.6%$0.400$0.410$0.380157,900
$0.390-0.010-2.5%$0.410$0.410$0.39095,800
$0.400+0.020+5.3%$0.370$0.410$0.370217,100
$0.380-0.030-7.3%$0.420$0.430$0.360256,500
$0.410-0.100-19.6%$0.450$0.450$0.3301,338,600
$0.510-0.090-15.0%$0.590$0.610$0.470489,400
$0.600-0.010-1.6%$0.620$0.620$0.570123,000
$0.610-0.030-4.7%$0.640$0.690$0.590210,300
$0.640-0.030-4.5%$0.680$0.690$0.630127,800
$0.670-0.040-5.6%$0.720$0.720$0.65095,900
$0.710-0.030-4.1%$0.710$0.820$0.610426,500
$0.740-0.010-1.3%$0.790$0.790$0.720141,900
$0.750-0.040-5.1%$0.770$0.770$0.730181,900
$0.790-0.010-1.3%$0.810$0.820$0.720556,300
$0.800-0.030-3.6%$0.840$0.840$0.800100,200
$0.830-0.010-1.2%$0.860$0.860$0.83037,900
$0.840+0.010+1.2%$0.830$0.860$0.83092,200
$0.8300.0000.0%$0.820$0.840$0.800165,500
$0.8300.0000.0%$0.840$0.860$0.800158,300
$0.830-0.050-5.7%$0.900$0.960$0.810286,100
$0.880-0.070-7.4%$0.970$0.990$0.860308,400
$0.950-0.050-5.0%$1.000$1.010$0.940138,100
$1.000+0.030+3.1%$0.980$1.070$0.970159,200
$0.970-0.030-3.0%$1.040$1.070$0.950183,700
$1.000-0.090-8.3%$1.110$1.130$1.000121,500
$1.090-0.030-2.7%$1.120$1.180$1.070138,600
$1.120-0.010-0.9%$1.080$1.150$1.070180,000
$1.130+0.010+0.9%$1.120$1.210$1.080156,700
$1.120-0.010-0.9%$1.160$1.190$1.110134,100
$1.130-0.030-2.6%$1.180$1.250$1.130131,100
$1.160-0.040-3.3%$1.210$1.240$1.110146,600
$1.200-0.070-5.5%$1.340$1.340$1.180188,400
$1.270-0.080-5.9%$1.320$1.350$1.260144,500
$1.350-0.020-1.5%$1.370$1.390$1.30096,900
$1.370-0.010-0.7%$1.420$1.420$1.350126,000
$1.380-0.040-2.8%$1.460$1.480$1.38085,300
$1.420-0.070-4.7%$1.450$1.470$1.40065,100
$1.4900.0000.0%$1.480$1.530$1.41035,800
$1.490-0.010-0.7%$1.510$1.580$1.450119,300
$1.500-0.040-2.6%$1.560$1.590$1.400287,400
$1.540-0.050-3.1%$1.590$1.610$1.510105,400
$1.590+0.010+0.6%$1.610$1.640$1.550142,400
$1.5800.0000.0%$1.600$1.650$1.51082,800
$1.580-0.030-1.9%$1.630$1.660$1.500211,600
$1.610-0.110-6.4%$1.710$1.720$1.590133,500

Splits

2 splits since 2018 · NASDAQ:CRIS · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-5Consolidation
Ticker
Munich:CUS0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Latest news

All Curis, Inc. news

Curis, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 116 in all · newest Nov 12, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Nov 12, 2026
Decks
79 decks · latest July 2026

Where Curis, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRIS · Home listingNASDAQUnited StatesUSD
gettex:CUS0gettexGermanyEUR
Lang & Schwarz:A3ETJDLang & SchwarzGermanyEUR
LS Exchange:A3ETJDLS ExchangeGermanyEUR
BOATS:CRISBOATSUnited StatesUSD
Stuttgart:CUS0StuttgartGermanyEUR
Dusseldorf:CUS0DusseldorfGermanyEUR
Tradegate:CUS0TradegateGermanyEUR
Frankfurt:CUS0FrankfurtGermanyEUR
Hamburg:CUS0HamburgGermanyEUR
Munich:CUS0 · This pageMunichGermanyEUR

Valuation

Price/book 1.1× against a median of 1.1×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$1.42M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
1.85

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Curis, Inc. · NASDAQ:CRISUS$2.85M−US$1.42Mn/an/an/a1.1×n/a0.3×1.85
Skye Bioscience, Inc. · NASDAQ:SKYEUS$3.10M−US$1.71Mn/an/an/a2.3×n/a0.0×0.85
Creative Medical Technology Holdings, Inc. · NASDAQ:CELZUS$3.06M−US$3.79Mn/a−1,263×n/a0.4×n/a0.0×1.53
Oncology Pharma Inc. · OTC:ONPHUS$3.04Mn/an/an/an/an/an/an/a1.62
Imunon, Inc. · NASDAQ:IMNNUS$3.00MUS$5.90Mn/an/an/a1.1×n/a2.6×0.57
Gelteq Limited · NASDAQ:GELSUS$2.89MUS$6.27Mn/a57.2×n/a0.3×n/a0.4×0.83
Fluicell AB · OMXSTO:FLUIUS$2.83MUS$3.03M10.4×1.6×10.7×1.8×14.1%0.1×n/a
Alligator Bioscience AB · OMXSTO:ATORXUS$2.79MUS$1.47Mn/a53.3×n/a1.2×n/a1.2×n/a
Traws Pharma, Inc. · NASDAQ:TRAWUS$2.69MUS$351,448n/an/an/an/an/an/a2.07
NextCell Pharma AB · OMXSTO:NXTCLUS$2.69MUS$626,140n/a0.6×n/a0.6×−440.8%0.0×n/a
Bioxytran, Inc. · OTC:BIXTUS$2.66MUS$2.59Mn/an/an/an/an/an/a-1.20
Median of the othersUS$2.86MUS$1.47M10.4×1.6×10.7×1.1×−213.3%0.1×0.85

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
42.50 USD · Analysts' mean
EPS, year to Dec 2026
-32.48 · 1 analyst
Revenue, year to Dec 2026
1.75M · 4 analysts

Team and board

OfficerRole
James DentzerPresident & CEO
Diantha DuvallChief Financial Officer
Maureen E. LaneVice President, Clinical and Translational Science
Nick PelletierVice President, Clinical Operations
Ahmed HamdyChief Medical Officer
Jonathan ZungChief Development Officer

Events

Calls

CallWhenStatus
Curis (NASDAQ:CRIS) Q3 2026 Earnings CallThu, Nov 12, 2026 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q1 2026 Earnings CallTue, May 12, 2026 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q4 2025 Earnings CallThu, Mar 19, 2026 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q3 2025 Earnings CallThu, Nov 06, 2025 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q2 2025 Earnings CallTue, Aug 05, 2025 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q1 2025 Earnings CallTue, May 06, 2025 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q4 2024 Earnings CallMon, Mar 31, 2025 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q3 2024 Earnings CallThu, Nov 14, 2024 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q2 2024 Earnings CallThu, Aug 01, 2024 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q1 2024 Earnings CallTue, May 07, 2024 · 8:30 AM ETReplay
All 26 calls
CallWhenStatus
Curis (NASDAQ:CRIS) Q4 2023 Earnings CallThu, Feb 08, 2024 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q3 2023 Earnings CallThu, Nov 02, 2023 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q2 2023 Earnings CallThu, Aug 03, 2023 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q1 2023 Earnings CallThu, May 04, 2023 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q4 2022 Earnings CallMon, Mar 13, 2023 · 8:30 AM ETReplay
Curis (NASDAQ:CRIS) Q3 2022 Earnings CallWed, Nov 09, 2022 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q1 2022 Earnings CallThu, May 05, 2022 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q4 2021 Earnings CallThu, Feb 24, 2022 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q3 2021 Earnings CallTue, Nov 09, 2021 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q2 2021 Earnings CallTue, Aug 03, 2021 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q1 2021 Earnings CallWed, May 12, 2021 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q4 2020 Earnings CallTue, Mar 16, 2021 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q3 2020 Earnings CallTue, Nov 10, 2020 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q2 2020 Earnings CallTue, Aug 04, 2020 · 4:30 PM ETReplay
Curis (NASDAQ:CRIS) Q1 2020 Earnings CallTue, May 12, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−21.1%
Q2 2026Aug 14, 2026 · After close0.0%
Q1 2026May 12, 2026 · After close−9.1%
Q4 2025Mar 20, 2026−2.6%
Q3 2025Nov 6, 2025 · After close−10.3%
Q2 2025Aug 5, 2025 · Before open+4.4%
Q1 2025May 6, 2025 · Before open−10.6%
Q4 2024Mar 31, 2025−37.1%
Q3 2024Nov 14, 2024 · Before open+1.3%
Q2 2024Aug 1, 2024 · Before open−9.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open+0.2%
Q4 2023Feb 8, 2024 · Before open+13.4%
Q3 2023Nov 2, 2023 · Before open−4.3%
Q2 2023Aug 3, 2023 · After close−9.1%
Q1 2023May 4, 2023 · After close−3.6%
Q4 2022Mar 13, 2023 · Before open−7.9%
Q3 2022Nov 9, 2022 · After close+13.9%
Q2 2022Aug 4, 2022 · After close+1.0%
Q1 2022May 5, 2022 · After close−4.4%
Q4 2021Feb 24, 2022 · After close+0.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck31 slidesJuly 2026
Investor Presentation (June 2026)Investor deck31 slidesJune 2026
Q1 2026 Earnings PresentationEarnings32 slidesMay 12, 2026
Investor Presentation (May 2026)Investor deck32 slidesMay 2026
Investor Presentation (March 2026)Investor deck32 slidesMarch 2026
Investor Presentation (November 2025)Investor deck31 slidesNovember 2025
Investor Presentation (October 2025)Investor deck30 slidesOctober 2025
Investor Presentation (September 2025)Investor deck31 slidesSeptember 2025
Investor Presentation (July 2025)Investor deck31 slidesJuly 2025
Q1 2025 Earnings PresentationEarnings40 slidesMay 6, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (April 2025)Investor deck40 slidesApril 2025
Investor Presentation (January 2025)Investor deck42 slidesJanuary 2025
Investor Presentation (December 2024)Investor deck41 slidesDecember 2024
Investor Presentation (November 2024)Investor deck39 slidesNovember 2024
Investor Presentation (November 2024)Investor deck41 slidesNovember 2024
Investor Presentation (October 2024)Investor deck39 slidesOctober 2024
Investor Presentation (October 2024)Investor deck38 slidesOctober 2024
Investor Presentation (September 2024)Investor deck37 slidesSeptember 2024
Investor Presentation (August 2024)Investor deck36 slidesAugust 2024
Technical Presentation (August 2024)Technical14 slidesAugust 2024
Investor Presentation (May 2024)Investor deck45 slidesMay 2024
Investor Presentation (March 2024)Investor deck19 slidesMarch 2024
Investor Presentation (January 2024)Investor deck17 slidesJanuary 2024
Technical Presentation (September 2023)Technical192 slidesSeptember 2023
Investor Presentation (September 2023)Investor deck16 slidesSeptember 2023
Investor Presentation (July 2023)Investor deck20 slidesJul 6, 2023
DAVA Oncology 2023 Bermuda Heme ConferenceConference13 slidesJuly 2023
Investor Presentation (April 2023)Investor deck27 slidesApril 2023
Technical Presentation (December 2022)Technical6 slidesDec 12, 2022
Investor Presentation (December 2022)Investor deck23 slidesDecember 2022
Investor Presentation (November 2022)Investor deck23 slidesNovember 2022
Investor Presentation (September 2022)Investor deck50 slidesSeptember 2022
EHA 2022 Hybrid CongressConference15 slidesJun 11, 2022
Investor Presentation (June 2022)Investor deck50 slidesJun 1, 2022
Investor Presentation (May 2022)Investor deck45 slidesMay 2022
Investor Presentation (February 2022)Investor deck45 slidesFebruary 2022
Technical Presentation (January 2022)Technical40 slidesJan 6, 2022
Investor Presentation (January 2022)Investor deck48 slidesJanuary 2022
Technical Presentation (2022)Technical13 slides2022
Technical Presentation (2022)Technical9 slides2022
Investor Presentation (August 2021)Investor deck33 slidesAugust 2021
EHA 2021Conference18 slidesJun 11, 2021
Investor Presentation (May 2021)Investor deck34 slidesMay 2021
Technical Presentation (2021)Technical22 slides2021
Technical Presentation (2021)Technical9 slides2021
Technical Presentation (2021)Technical9 slides2021
Investor Presentation (December 2020)Investor deck34 slidesDecember 2020
Technical Presentation (December 2020)Technical13 slidesDecember 2020
Investor Presentation (November 2020)Investor deck28 slidesNovember 2020
Investor Presentation (August 2020)Investor deck28 slidesAugust 2020

This page holds 50 of 79 decks. Open Decks

Open Decks

Financings

RaiseDate
Private placement of shares of common stock (or pre-funded warrants) and accompanying common warrants
Announced: about US$8.5M · US$0.51 a share · ½ warrant at US$0.6 for 66 months · A.G.P./Alliance Global Partners +1
Dealers: A.G.P./Alliance Global Partners (lead), Laidlaw & Company (UK) Ltd.
Use of proceeds: Research and development, working capital and general corporate purposes
Oct 16, 2026
Public offering of common stock (or pre-funded warrants) and accompanying common warrants
Announced: about US$5.6M · US$1.5 a share · Warrants at US$1.75 for 60 months · A.G.P./Alliance Global Partners +1
Dealers: A.G.P./Alliance Global Partners (lead), Laidlaw & Company (UK) Ltd.
Use of proceeds: Fund research and development activities, working capital and general corporate purposes
Aug 13, 2026
Private placement of private placement (PIPE financing)
Closed: US$20.2M raised · US$1,000 a share · Warrants at US$0.75 · Laidlaw & Company (UK) Ltd.
Dealers: Laidlaw & Company (UK) Ltd. (lead)
Buyers: Nantahala Capital; Stonepine Capital Management; Pointillist Partners, LLC; The Red Hook Fund, LP
Insiders: Members of the Company's management team and board of directors participated.
Use of proceeds: Research and development, general corporate expenses and working capital
Jan 9, 2026
Registered direct offering of common stock, with concurrent private placement of pre-funded and common warrants
Announced: about US$7M · US$2.275 a share · Warrants at US$2.15 for 60 months · Laidlaw & Company (U.K.) Ltd. +1
Dealers: Laidlaw & Company (U.K.) Ltd., Jones
Use of proceeds: Research, development, working capital and other general corporate purposes
Jul 2, 2025
Registered direct offering of common stock, with concurrent private placement
Closed: US$8.8M raised
Use of proceeds: To fund planned operations into the fourth quarter of 2025
May 6, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue9.44M10.9M10.0M10.2M10.6M10.8M10.0M10.4M9.90M7.53M
Cost of revenue45.0K98.0K229.0K257.0K533.0K534.0K503.0K563.0K496.0K399.0K
Gross profit9.40M10.8M10.0M9.90M10.1M10.3M9.50M9.87M9.40M7.13M
Research and development28.3M38.6M39.5M43.3M34.9M23.1M22.3M24.4M45.1M18.0M
Selling, general and administrative14.0M16.8M18.6M19.6M17.3M12.1M11.6M14.8M25.8M15.6M
Operating income-5.71M-44.5M-48.3M-53.0M-42.1M-24.9M-24.4M-29.3M-49.8M-58.0M
Depreciation and amortization169.0K203.0K255.0K233.0K158.0K144.0K125.0K177.0K235.0K193.0K
EBITDA-5.54M-44.3M-48.1M-52.8M-41.9M-24.8M-24.2M-29.2M-49.5M-57.8M
Interest expense2.19M615.0K2.02M4.77M00791.0K3.93M3.97M2.78M
Income before tax-7.58M-43.4M-47.4M-56.7M-45.4M-29.9M-32.1M-32.6M-53.3M-60.4M
Income tax00-255.0K3.65M5.20M4.97M4.66M683.0K3.86M2.58M
Net income-7.58M-43.4M-47.4M-56.7M-45.4M-29.9M-32.1M-32.6M-53.3M-60.4M
Earnings per share, basic-0.58-6.88-8.96-12.140.50-0.61-0.97-0.98-1.79-0.45
Earnings per share, diluted-0.58-6.88-8.96-12.140.50-0.61-0.97-0.98-1.79-0.45

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.06M20.0M26.7M19.7M40.0M129.6M15.4M23.6M38.3M26.0M
Short-term investments029.7M66.0M75.9M38.9M5.11M634.0K21.9M18.4M
Receivables03.35M2.79M2.98M3.22M3.04M3.24M2.86M3.07M2.46M
Inventory-2.89M-2.89M-2.54M-399.0K-94.0K-827.0K0-1.26M
Current assets6.92M26.4M60.9M92.1M122.4M172.8M25.0M28.0M64.3M48.2M
Property, plant and equipment62.0K231.0K434.0K689.0K505.0K663.0K154.0K267.0K366.0K413.0K
Goodwill8.98M8.98M8.98M8.98M8.98M8.98M8.98M8.98M8.98M8.98M
Total assets20.0M41.3M77.3M108.8M162.3M204.4M35.1M37.4M73.8M57.8M
Accounts payable5.61M3.02M3.17M3.19M6.42M4.17M4.46M2.91M5.42M5.88M
Current liabilities14.1M19.0M22.0M10.0M13.4M10.1M6.54M13.3M14.1M13.5M
Long-term debt334.0K028.6M35.7M14.9M
Total debt07.56M8.50M6.74M0891.0K035.5M41.6M19.9M
Total liabilities14.5M47.3M57.6M62.3M71.6M73.7M69.0M41.9M49.8M28.5M
Shareholders' equity5.46M-6.00M19.7M46.6M90.7M130.7M-33.9M-4.50M24.0M29.5M
Shares outstanding646.5K8.49M5.89M4.83M91.6M91.5M33.2M33.2M32.8M141.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-27.2M-39.6M-38.4M-54.3M-37.6M-25.7M-26.2M-30.1M-48.4M-35.8M
Capital spending000-416.0K0-677.0K-41.0K-85.0K-188.0K-329.0K
Free cash flow-27.2M-39.6M-38.4M-54.8M-37.6M-26.4M-26.2M-30.1M-48.5M-36.1M
Cash from investing2.50M29.4M37.8M33.0M-47.9M-49.0M-4.46M21.4M-3.63M30.1M
Cash from financing9.77M3.44M7.58M867.0K-4.17M188.8M23.3M-5.96M64.2M-1.37M
Dividends paid00
Share buybacks5.84M300.0K158.7M68.0K143.0K42.7M2.91M
Change in cash-14.9M-6.68M6.93M-20.4M-89.7M114.0M-7.39M-14.7M12.3M-7.05M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
S-8 POSNov 13, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 13, 2026Offer documentSEC
S-3 · Registration statementNov 13, 2026Offer documentSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
8-K · Current reportNov 6, 2026Current reportSEC
DEF 14A · Proxy statementNov 2, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 23, 2026Meeting noticeSEC
8-K · Current reportOct 19, 2026Material contractSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
424B4 · ProspectusAug 13, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 13, 2026Other filingsSEC
S-1 · Registration statementAug 10, 2026Offer documentSEC
8-K · Current reportJul 30, 2026Current reportSEC
DRS · Draft registration statementJul 17, 2026Offer documentSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
4 · Change in ownershipJul 9, 2026Insider tradeSEC
8-K · Current reportJul 2, 2026Current reportSEC
8-K/A · Current report, amendedJul 1, 2026Current reportSEC
8-K · Current reportJul 1, 2026Current reportSEC
8-K · Current reportJun 25, 2026Meeting outcomeSEC
DEF 14A · Proxy statementJun 5, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 22, 2026Meeting noticeSEC
8-K · Current reportMay 22, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
8-K · Current reportMay 1, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeApr 24, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 27, 2026Big-stake noticeSEC
10-K · Annual reportMar 24, 2026Annual reportSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 23, 2026Other filingsSEC
8-K · Current reportMar 19, 2026ResultsSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
8-K · Current reportMar 17, 2026Management or board changeSEC
CORRESP · Letter to the SECMar 17, 2026Other filingsSEC
DEF 14A · Proxy statementFeb 19, 2026Meeting noticeSEC
UPLOAD · Letter from the SECFeb 19, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
S-3 · Registration statementFeb 13, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementFeb 9, 2026Meeting noticeSEC
8-K · Current reportFeb 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 23, 2026Big-stake noticeSEC
8-K · Current reportJan 7, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K/A · Current report, amendedNov 13, 2025Current reportSEC
S-8 · Registration statement for employee plansNov 6, 2025Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 24, 2025Current reportSEC
8-K · Current reportAug 22, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 19, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
CORRESP · Letter to the SECAug 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
S-1 · Registration statementAug 8, 2025Offer documentSEC
8-K · Current reportAug 8, 2025Current reportSEC
424B5 · ProspectusAug 8, 2025Offer documentSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
424B5 · ProspectusJul 2, 2025Offer documentSEC
FWP · Free writing prospectusJul 2, 2025Offer documentSEC
8-K · Current reportJul 2, 2025Material contractSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
8-K · Current reportMay 22, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveMay 20, 2025Other filingsSEC
CORRESP · Letter to the SECMay 15, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECMay 13, 2025Other filingsSEC
S-3 · Registration statementMay 6, 2025Offer documentSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 16, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 10, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMar 31, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementMar 31, 2025Meeting noticeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
424B5 · ProspectusMar 31, 2025Offer documentSEC
FWP · Free writing prospectusMar 28, 2025Offer documentSEC
8-K · Current reportMar 28, 2025ResultsSEC
8-K · Current reportFeb 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJan 8, 2025Other filingsSEC
CORRESP · Letter to the SECJan 3, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 31, 2024Other filingsSEC
S-3 · Registration statementDec 23, 2024Offer documentSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 1, 2024Big-stake noticeSEC
424B5 · ProspectusOct 30, 2024Offer documentSEC
8-K · Current reportOct 29, 2024Material contractSEC
FWP · Free writing prospectusOct 28, 2024Offer documentSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
S-8 · Registration statement for employee plansJun 14, 2024Offer documentSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
8-K · Current reportMay 23, 2024Management or board changeSEC
8-K · Current reportMay 14, 2024Current reportSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
SC 13G · Big-stake noticeApr 15, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveApr 15, 2024Other filingsSEC
CORRESP · Letter to the SECApr 10, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 10, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 29, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECFeb 13, 2024Other filingsSEC
SC 13G · Big-stake noticeFeb 12, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansFeb 8, 2024Offer documentSEC
S-3 · Registration statementFeb 8, 2024Offer documentSEC
10-K · Annual reportFeb 8, 2024Annual reportSEC
8-K · Current reportFeb 8, 2024ResultsSEC
8-K · Current reportJan 11, 2024Current reportSEC
UPLOAD · Letter from the SECJan 3, 2024Other filingsSEC
CORRESP · Letter to the SECDec 21, 2023Other filingsSEC
10-K/A · Annual report, amendedDec 21, 2023Annual reportSEC
UPLOAD · Letter from the SECDec 12, 2023Other filingsSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
8-K · Current reportNov 2, 2023ResultsSEC
8-K/A · Current report, amendedSep 28, 2023Meeting outcomeSEC
8-K · Current reportSep 28, 2023Meeting outcomeSEC
DEF 14A · Proxy statementAug 18, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementAug 4, 2023Meeting noticeSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
424B5 · ProspectusJul 6, 2023Offer documentSEC
8-K · Current reportJul 6, 2023Material contractSEC
8-K · Current reportJul 6, 2023Current reportSEC
8-K · Current reportMay 30, 2023Meeting outcomeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Curis, Inc.’s releases · as of Oct 16, 2026

Common shares
6,679,229
Fully diluted
6,699,424

Fully diluted

LineSharesAs of
Common shares6,679,229
Warrants20,195Jan 8, 2026

Warrants and options

Lot
Warrants · US$0.75 · expiry not stated

Share count over time

CountShares
Nov 22, 20266,679,229
Jun 26, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund216K2.3%US$113KJun 30, 2026
Fidelity Extended Market Index Fund116K1.2%US$66,050May 31, 2026
Vanguard Extended Market Index Fund96,0431.0%US$50,144Jun 30, 2026
Fidelity Series Total Market Index Fund17,6930.19%US$10,032May 31, 2026
Fidelity Total Market Index Fund10,2080.11%US$5,788May 31, 2026
Fidelity Nasdaq Composite Index Fund2,8390.03%US$1,610May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Kaitin Kenneth I
Director
Buy10,000USD 0.55US$5,500Mar 31, 2026

Big stakes

StakeStakeSharesDateFiling
Nantahala Capital Management, LLC9.99%4.22MMar 31, 2026Schedule 13G
Thomas A. Satterfield, Jr.9.90%3.96MMar 31, 2026Schedule 13G
Stonepine Capital Management, LLC9.90%4.03MMar 17, 2026Schedule 13G
Bleichroeder LP9.90%1.04MMar 31, 2025Schedule 13G
NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP6.98%2.94MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John Hohneker
Other companies: ArriVent BioPharma, Inc. (Director · Since at least May 16, 2024); Carisma Therapeutics, Inc. (Director · Apr 1, 2024 – Jun 26, 2024 · Past); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past)
Director · Since at least Dec 2, 2021
Lori Kunkel
Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); ORIC Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2020); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 19, 2025 · Past); Tocagen Inc (Director · Jun 21, 2018 – Oct 4, 2019 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past)
Director · Jan 22, 2018 – Jan 31, 2022 · Past
Mani Mohindru
Other companies: Cardiff Oncology, Inc. (President & Chief Executive Officer · Since at least Jun 10, 2021); CytomX Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Tvardi Therapeutics, Inc. (CFO & Chief Strategy Officer · Aug 15, 2017 – Dec 2, 2019 · Past)
Chief Strategy Officer · Jan 19, 2016 – Feb 14, 2017 · Past
Anne Borgman
Other companies: NextCure, Inc. (Director · Since at least Jun 23, 2022); Sutro Biopharma, Inc. (CHIEF MEDICAL OFFICER · Feb 28, 2023 – May 1, 2025 · Past)
Director · Since at least Oct 12, 2022
Joseph Md Phd Davie
Other companies: Armata Pharmaceuticals, Inc. (Director · May 8, 2006 – May 29, 2009 · Past); CV Therapeutics Inc (Director · Jan 13, 2006 – Apr 14, 2009 · Past)
Director · Jan 25, 2008 – Jan 7, 2011 · Past
Ahmed Hamdy
Other companies: Vincerx Pharma Inc (Chief Executive Officer, Director · Jun 29, 2021 – Aug 12, 2024 · Past)
Chief Medical Officer · Since at least May 1, 2025
James Dentzer
Other companies: Imunon, Inc. (Director · Since at least Sep 29, 2022)
President & CEO, Director · Since at least Jan 20, 2023
Jonathan Zung
Other companies: Evelo Biosciences, Inc. (Chief Development Officer · Jan 4, 2021 – Jul 19, 2022 · Past)
Chief Development Officer · Since at least May 1, 2023
Kenneth Pienta
Other companies: Cue Biopharma, Inc. (Chief Medical Officer · Dec 18, 2017 – Mar 25, 2022 · Past)
Director · Mar 7, 2013 – Feb 28, 2017 · Past
Robert Martell
Other companies: Indaptus Therapeutics, Inc. (Director · Since at least Feb 13, 2023)
Head of Research & Development · Sep 14, 2011 – Jan 20, 2023 · Past
All 23 people
PersonSeat
Stephen Carter
Other companies: Vion Pharmaceuticals Inc (Director · Jun 27, 2007 – Jun 27, 2007 · Past)
Director · Dec 17, 2007 – Jan 25, 2008 · Past
Ali Ph D FattaeyPresident & CEO, Director · Feb 19, 2013 – May 15, 2018 · Past
Changgeng QianVP, Research & Preclinical Dev · Oct 24, 2008 – Jan 7, 2011 · Past
Diantha DuvallCFO · Since at least Aug 5, 2022
Joseph M DavieDirector · Jun 1, 2006 – Jun 6, 2007 · Past
Kenneth I KaitinDirector · Since at least Mar 31, 2026
Marc RubinDirector · Since at least May 20, 2025
Martyn D GreenacreDirector · Since at least May 21, 2024
Mary Elizabeth PotthoffVP and General Counsel · May 31, 2006 – May 31, 2006 · Past
Maureen E. LaneVice President, Clinical and Translational Science · Since at least Nov 4, 2026
Mitchell KeeganVice-President · Sep 2, 2009 – Jan 7, 2011 · Past
Nick PelletierVice President, Clinical Operations · Since at least Nov 4, 2026
William SteinkraussChief Financial Officer · Sep 10, 2019 – Jan 29, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Curis, Inc.